Bristol-Myers Squibb will sell its active pharmaceutical ingredients manufacturing facility in Swords, Co Dublin to SK Biotek, a south Korean biotechnology firm.
The facility manufactures ingredients for a number of meds including BMS' blockbuster drug, Eliquis, used to lower the risk of stroke by blood clot.
SK Biotek will operate the plant as a standalone contract development manufacturing organization and will continue to manufacture the current portfolio of small molecule pharmaceutical products at the site. The CDMO also intends to add marketing, R&D talent, and invest in upgrades to bring additional capacity to the site.
The companies plan to complete the deal by the fourth quarter 2017
Read the Irish Times coverage